Is it possible that these concerns raised by EMEA are normal for biologics undergoing scrutiny during the approval process. Essentially, the requests for clarification/additional data are normal in an approval process. INSM had premonitions of its settlement with TRCA/DNA, and decided not to invest additional time/$$ in the EMEA application. Therefore, EMEA's picture of Iplex is deficient.
News 
Market Data 
Discover 
AI
